Introduction {#S1}
============

Sleep apnea syndrome (SAS) is a disorder characterized by repeated pauses in breathing during sleep ([@B52]). It is often underdiagnosed ([@B40]), though its prevalence is increasing and was recently shown to be up to 40% in the general population ([@B17]), and likely higher in the elderly population ([@B1]; [@B17]). SAS interrupts sleep and causes intermittent hypoxia ([@B44]) which could contribute to a range of pathophysiological consequences, including cognitive impairment ([@B49]; [@B4]), particularly in older patients ([@B51]; [@B39]; [@B48]). In fact, SAS is more prevalent in patients suffering from neurodegenerative diseases ([@B35]; [@B11]) and is suspected to increase risks of developing Alzheimer's disease ([@B3]; [@B39]; [@B27]).

The association between SAS and neurodegenerative diseases remains controversial ([@B46]; [@B44]) and the pathophysiological consequences of SAS are still unclear ([@B51]; [@B54]; [@B30]; [@B6]). This is further complicated by the fact that most studies do not distinguish between the more common obstructive form (OSAS), characterized by recurrent collapse of the upper respiratory tract, and the rarer central form (CSAS), characterized by repetitive pauses in breathing without respiratory effort. Moreover, the causes of cognitive impairments are difficult to establish in patients over 70 years old, who often exhibit multiple co-morbidities.

Validated modifiable risk factors can be used to mitigate the progression of age-related cognitive decline. For instance, OSAS is associated with Alzheimer's disease biomarker accumulation ([@B6]) and can be treated with continuous positive airway pressure (CPAP) ([@B29]; [@B9]; [@B26]; [@B43]), which improves cognitive function in patients suffering from Alzheimer's disease, although its effect on pathological progression remains unknown ([@B2]; [@B47]; [@B10]). The purpose of this exploratory study was therefore to (a) assess the prevalence of each form of SAS in a cohort of elderly patients (\>70 years old) admitted to our geriatric unit for non-acute reasons, and (b) investigate the independent relation between sleep apnea and cognitive performance, measured using validated tests, including the Mini Mental-State Exam (MMSE), the Mattis Dementia rating Scale (MDRS) and the Stroop test, and competing against known risk factors for cognitive impairment. The hypothesis was that (i) the prevalence of SAS in elderly patients consulting for cognitive deficit would be greater than that reported for the general population and (ii) elderly patients with SAS would have significantly worse MMSE, MDRS and Stroop test scores, independently of confounding factors.

Materials and Methods {#S2}
=====================

We enrolled 115 consecutive patients admitted to our geriatric unit for non-acute reasons (non-emergency, no surgery, no mandatory overnight stay) between October 2015 and March 2018. The inclusion criterion was patients aged over 70 years. The exclusion criteria were (i) refusal to undergo sleep apnea diagnosis with overnight polygraph recording (26 patients), or (ii) refusal or inability to complete neurocognitive assessment using structural cerebral magnetic resonance imaging (MRI) (12 patients). In addition, 1 patient died before completing the cognitive assessment, which left a study cohort of 76 patients ([Figure 1](#F1){ref-type="fig"}), who underwent overnight ambulatory polygraphy (Weinmann SOMNOlab 2, Hamburg, Germany) to measure their Apnea-Hypopnea Index (AHI), total number of events per night, mean arterial blood oxygen saturation (SaO~2~) and sleep time at SaO~2~ below 90% ([@B25]). Apnea severity was noted based on the AHI, as mild (AHI 5--15), moderate (AHI 16--30), or severe (AHI \> 30). Apneas were defined as cessation of airflow for at least 10 s and hypopneas were defined as a reduction of airflow to ≤50% of baseline for at least 10 s ([@B46]). The final diagnosis of sleep apnea, obstructive (OSAS) or central (CSAS) was determined by a pulmonologist (YD) based on the relative number of obstructive or central events per night, based on the definition by [@B46]: obstructive sleep apnea is characterized by ongoing ventilatory effort while central sleep apnea is characterized by withdrawal of central respiratory drive. OSAS and CSAS were defined when a patient had 5 or more episodes of obstructive or central apneas per hour of sleep, respectively.

![Flowchart of patient inclusions and exclusions.](fnagi-11-00361-g001){#F1}

The patient's overall cognitive function was assessed by clinical psychologists (IG and ASM) using the following validated scores: (a) Mini-Mental State Examination (MMSE) ([@B22]), which ranges from 0 to 30 points. Patients scoring ≤23 considered cognitively impaired. (b) MDRS, which comprises five subscales, spanning the areas of attention, initiation-perseveration, construction, conceptualization and memory ([@B18]; [@B15]). ([@B17]) Stroop Colors and Words test was used to assess attention and executive functioning ([@B8]), which are known to be affected by sleep apnea ([@B38]; [@B30]; [@B44]). The Colors test asks patients to recognize the color of dots that appear for a short time, while the Words test asks them to read words (names of colors) that appear for a short time. The Interference test requires the patients to read the words (names of colors) written in different (wrong) colors and repress the wrong answer (Stroop interference effect). For all tests, the delay before the answer, and the number of uncorrected mistakes, are reported. ([@B1]) Montgomery-Asberg Depression rating scale \[MADRS ([@B34])\], on 60 points, and Goldberg anxiety scale ([@B20]) on nine points, to rule out effects of depression or anxiety on cognitive test results.

Final etiological diagnosis of cognitive impairment was based on the neurocognitive assessments, as well as MRI (Siemens Avanto 27780, Munich, Germany) results and history of geriatric consultations. Mild cognitive impairment was diagnosed following the criteria of [@B41], while Alzheimer's disease (AD) and AD-like diseases were diagnosed according to the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) and the recommendations of the National Institute on Aging -- Alzheimer's Association workgroups ([@B31]).

Vascular risk factors for the development of AD ([@B51]) were diagnosed based on a comprehensive assessment performed in our geriatric unit. Blood samples were obtained after a minimum of 10 h of fasting. The diagnosis of vitamin D \[25(OH)D~3~\] deficiency was given if blood measurements were below 30 ng/mL, diabetes was diagnosed with blood glucose levels above 7 mmol/L and anemia with hemoglobin levels below 12 (women) or 13 (men) g/dL. Likewise, the reference range was 4.1--6.5 mmol/L for total cholesterol and 0.6--1.8 mmol/L for triglycerides. Inflammation was diagnosed if the blood levels of C-reactive protein (CRP) was higher than 10 mg/L ([@B32]) as per the recommendations of the World Health Organization ([@B50]), and leucocyte concentration was higher than 100000/mm^3^. The blood pressure of patients was measured during waking hours, and after polygraphy, during night-time hours.

Written informed consent was obtained from all patients for their participation and confirmed by their next-of-kin if necessary. The study protocol was approved by an independent Ethical Review Board (CPP Amiens: 2015/6) and the national Data Protection Authority (CNIL:150075B-31). The study was registered in [clinicaltrials.gov](https://clinicaltrials.gov/) (NCT02578303). All procedures were performed in accordance with the 1964 Helsinki declaration.

Statistical Analysis {#S2.SS1}
--------------------

Descriptive statistics were used to summarize the data. Shapiro--Wilk tests were used to assess the normality of distributions. Due to skewed distribution of continuous variables, the data was presented as median \[IQR\]. Univariable regressions were performed to determine associations between five outcomes (MMSE, MDRS and Stroop Colors, Words, and Interference tests) and seventeen independent variables (age, BMI, sex, diagnosis of SAS, OSAS, or CSAS, AHI, sleep apnea severity, blood oxygen saturation, sleep time with hypoxia, number of events per night, diabetes, inflammation, hypercholesterolemia, hypertriglyceridemia, vitamin D deficiency, and anemia). Variables that do not measure sleep apnea were included because they represent cardiovascular risk factors known to affect sleep apnea or cognition in elderly patients ([@B13]). Multivariable regressions were then performed after backward selection (criterion *p* \< 0.15). Hypercholesterolemia was excluded from the multivariable models due to a low incidence (*n* \< 10) in our cohort. Sample size of 47 patients was calculated to be sufficient to show even the moderate negative correlation between the MDRS and the AHI with 80% power and 5% significance. Therefore, our sample size of 76 was deemed sufficient for analysis, considering a probably high failure rate in the neurocognitive tests due to the age of the patients. Statistical analyses were performed using R version 3.3.2 (R Foundation for Statistical Computing, Vienna, Austria). *P*-values \< 0.05 were considered statistically significant.

Results {#S3}
=======

The final cohort comprised 58 women (76%) and 18 men (24%), aged 84 \[IQR, 80--88\] years (range, 73--96), with BMI 24 \[IQR, 21--27\] kg/m^2^ (range, 15.6--40) ([Table 1](#T1){ref-type="table"}). Overall, they were not depressed (MADRS:6, IQR, 3--11; range, 0--31) nor anxious (Goldberg:3, IQR, 1--5; range, 0--9). A number of patients presented comorbidities, including heart failure (11.8%), aortic stenosis (3.9%), mitral stenosis (1.3%), carotid stenosis (3.9%), cerebral hematoma (3.9%), transient ischemic accident (3.9%), and cancer (25%). The prevalence of arterial hypertension was 32% while awake but rose to 59% while asleep. Thirty-three patients (43%) had mild cognitive impairment, 9 (12%) had vascular dementia, 7 (9%) had Alzheimer's disease, 1 (1%) had Lewy-body dementia, and 26 (34%) had mixed dementia.

###### 

Patient demographics.

                              Cohort (*n* = 76)                
  --------------------------- ------------------- ------------ ----------
  Age (years)                 84                  \[80--88\]   (73--96)
  BMI (kg/m^2^)               24                  \[21--27\]   (16--40)
  Depression (MADRS^∗^/60)    6                   \[3--11\]    (0--31)
  Anxiety (Goldberg/9)        3                   \[1--5\]     (0--9)
                              ***n***             **(%)**      
  Women                       58                  (76%)        
  Diabetes                    10                  (13%)        
  Hypercholesterolemia        5                   (7%)         
  Hypertriglyceridemia        18                  (24%)        
  Vitamin D deficiency        40                  (53%)        
  Anemia                      51                  (67%)        
  Hypertension (awake)        23                  (32%)        
  Hypertension (asleep)       41                  (59%)        
  **Diagnosis**                                                
  Mild cognitive impairment   33                  (43%)        
  Vascular dementia           9                   (12%)        
  Alzheimer's disease         7                   (9%)         
  Dementia with Lewy bodies   1                   (1%)         
  Mixed dementia              26                  (34%)        

∗

Montgomery-Asberg Depression Rating Scale. IQR, Interquartile range.

The median AHI was 16.4 (IQR, 5.4--35.3; range, 0.5--73), and indicated severe sleep apnea in 32 patients (42%) ([Table 2](#T2){ref-type="table"}). SAS was diagnosed in 48 patients (63%), of which 31 (41%) with OSAS and 17 (22%) with CSAS.

###### 

Sleep Apnea Syndrome.

                                       Cohort (*n* = 76)                 
  ------------------------------------ ------------------- ------------- ----------
  Blood oxygen saturation (SpO~2~,%)   95                  \[93--96\]    (87--98)
  Sleep time with hypoxia^∗^(%)        2                   \[1--7\]      (0--54)
  Number of events per night           56                  \[22--113\]   (2--548)
  Apnea-hypopnea index (AHI)           16                  \[5--35\]     (1--73)
                                       ***n***             **(%)**       
  **SAS severity (AHI**)                                                 
  None (\<5)                           19                  (25%)         
  Mild (5--15)                         18                  (24%)         
  Moderate (15--30)                    7                   (9%)          
  Severe (\>30)                        32                  (42%)         
  **Sleep Apnea Syndrome (SAS**)       48                  (63%)         
  Obstructive                          31                  (41%)         
  Central                              17                  (22%)         

∗

Hypoxia defined as a reduction of SpO2 by 10%. IQR, Interquartile range.

The median MMSE score was 22.5 (IQR, 19--26; range, 7--30), with 41 (54%) patients scoring ≤23 ([Table 3](#T3){ref-type="table"}). Univariable regression revealed the MMSE score to be associated with sex and diabetes ([Table 4](#T4){ref-type="table"}). There was no significant difference in MMSE between patients with moderate to severe SAS and patients with mild to no SAS ([Figure 2](#F2){ref-type="fig"}). Multivariable regression analysis revealed that MMSE decreased with age (β = −0.25, CI, −0.45 to −0.05; *p* = 0.014) and in patients with diabetes (β = −4.91, CI, −8.10 to −1.72; *p* = 0.01.

###### 

Cognitive Tests.

                                            Cohort (*n* = 76)                  
  ----------------------------------------- ------------------- -------------- -----------
  Mini-mental state exam (MMSE/30)          23                  \[19--26\]     (7--30)
  Mattis dementia rating scale (MDRS/144)   121                 \[109--132\]   (60--143)
  Stroop color and word test                                                   
  Colors (delay, s)                         19                  \[15--29\]     (6--70)
  Colors (non-corrected mistakes)           0                   \[0--0\]       (0--6)
  Words (delay, s)                          34                  \[25--50\]     (14--147)
  Words (non-corrected mistakes)            0                   \[0--1\]       (0--9)
  Interference (delay, s)                   53                  \[38--76\]     (15--116)
  Interference (non-corrected mistakes)     4                   \[1--13\]      (0--24)

IQR, Interquartile range.

###### 

Uni- and Multi-variable regression to identify factors associated with the Mini Mental State Exam (MMSE).

                                     Univariable   Multivariable (*n* = 71) Backward selection                                      
  ---------------------------------- ------------- --------------------------------------------- ------- ------- ------------------ -------
  Age                                −0.19         (−0.39 to 0.02)                               0.072   −0.25   (−0.45 to −0.05)   0.014
  BMI (kg/m^2^)                      0.14          (−0.09 to 0.37)                               0.226                              
  Female Gender                      −2.72         (−5.37 to 0.08)                               0.044                              
  SAS                                0.07          (−2.22 to 2.35)                               0.955                              
  OSAS                               −0.29         (−2.58 to 2.00)                               0.801                              
  CSAS                               0.92          (−1.86 to 3.70)                               0.510                              
  Apnea-hypopnea index (AHI)         0.01          (−0.05 to 0.07)                               0.723   0.04    (−0.01--0.10)      0.142
  **Sleep apnea severity**                                                                                                          
  *None*                             REF                                                                                            
  *Mild*                             1.11          (−2.08 to 4.31)                               0.489                              
  *Moderate*                         −3.44         (−7.90 to 1.01)                               0.128                              
  *Severe*                           0.35          (−2.46 to 3.15)                               0.806                              
  Blood oxygen saturation (SpO2,%)   −0.07         (−0.60 to 0.45)                               0.787                              
  Sleep time with hypoxia^∗^ (%)     0.01          (−0.07 to 0.10)                               0.738                              
  Number of events per night         0.00          (−0.01 to 0.01)                               0.438                              
  Diabetes                           −4.02         (−7.30 to −0.73)                              0.017   −4.91   (−8.10 to −1.72)   0.003
  Inflammation                       1.96          (−0.33 to 4.25)                               0.092                              
  Hypercholesterolemia^∗∗^           −0.83         (−5.31 to 3.65)                               0.712                              
  Hypertriglyceridemia               −0.89         (−3.58 to 1.79)                               0.508                              
  Vitamin D deficiency               1.17          (−1.09 to 3.44)                               0.304   1.83    (−0.33 to 4.00)    0.096
  Anemia                             0.17          (−2.26 to 2.59)                               0.892                              

∗

Hypoxia defined as a reduction of SpO2 by 10%.

∗∗

Excluded from multivariable analysis due to low incidence (\<10).
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The median MDRS score was 120.5 (IQR, 109.3--132.0; range, 60--143) ([Table 3](#T3){ref-type="table"}). Univariable regression revealed the MDRS to be associated with SAS, OSAS, AHI, diabetes, and hypertriglyceridemia ([Table 5](#T5){ref-type="table"}). The MDRS score was lower for patients with moderate to severe SAS compared to patients with mild to no SAS ([Figure 2](#F2){ref-type="fig"}; *p* = 0.009). Multivariable regression analysis revealed that MDRS decreased with age (β = −0.81, CI, −1.54 to −0.08; *p* = 0.031), in patients with OSAS (β = −10.03, CI, −18.26 to −1.80; *p* = 0.018), and in patients with diabetes (β = −16.10, CI, −27.8 to −4.36; *p* = 0.008).

###### 

Uni- and Multi-variable regression to identify factors associated with the Mattis Dementia Rating Scale (MDRS).

                                     Univariable   Multivariable (*n* = 66) Backward selection                                        
  ---------------------------------- ------------- --------------------------------------------- ------- -------- ------------------- -------
  Age                                −0.74         (−1.52 to 0.04)                               0.062   −0.81    (−1.54 to −0.08)    0.031
  BMI (kg/m^2^)                      0.14          (−0.77 to 1.06)                               0.755                                
  Female Gender                      −9.24         (−19.09 to 0.61)                              0.066                                
  SAS                                −8.78         (−17.50 to −0.05)                             0.049                                
  OSAS                               −9.94         (−18.72 to −1.17)                             0.027   −10.03   (−18.26 to −1.80)   0.018
  CSAS                               2.74          (−7.35 to 12.84)                              0.589                                
  Apnea-hypopnea index (AHI)         −0.23         (−0.44 to −0.01)                              0.039                                
  **Sleep apnea severity**                                                                                                            
  *None*                             REF                                                                                              
  *Mild*                             5.50          (−6.84 to 17.84)                              0.377                                
  *Moderate*                         −4.17         (−20.61 to 12.27)                             0.614                                
  *Severe*                           −9.36         (−20.06 to 1.33)                              0.085                                
  Blood Oxygen Saturation (SpO2,%)   0.83          (−1.25 to 2.90)                               0.430                                
  Sleep time with hypoxia^∗^ (%)     0.03          (−0.29 to 0.35)                               0.865                                
  Number of events per Night         0.01          (−0.03 to 0.04)                               0.745                                
  Diabetes                           −13.42        (−25.87 to −0.97)                             0.035   −16.10   (−27.8 to −4.36)    0.008
  Inflammation                       6.35          (−2.63 to 15.33)                              0.163                                
  Hypercholesterolemia^∗∗^           −10.83        (−27.46 to 5.79)                              0.198                                
  Hypertriglyceridemia               −9.99         (−19.91 to −0.07)                             0.048                                
  Vitamin D deficiency               0.07          (−9.39 to 8.35)                               0.907                                
  Anemia                             −4.93         (−14.35 to 4.49)                              0.300   −4.47    (−13.13 to 4.19)    0.306

∗

Hypoxia defined as a reduction of SpO2 by 10%.

∗∗

Excluded from multivariable analysis due to insufficient number of observations (\<10).

Twenty patients were unable to perform the Stroop test. For the remaining patients, the median Stroop Colors delay was 19 s (IQR, 15--29; range, 6--70) and the median number of mistakes was 0 (IQR, 0--0; range, 0--6) ([Table 3](#T3){ref-type="table"}). The Stroop Words delay was 34 s (IQR, 25--50; range, 14--147) and the median number of mistakes was 0 (IQR, 0--1; range, 0--9). The Stroop Interference delay was 53 s (IQR, 38--76; range, 15--116) and the median number of mistakes was 4 (IQR, 1--13; range, 0--24). Univariable regressions revealed the Stroop Colors delay to be associated with age, AHI, severe SAS, and anemia ([Table 6](#T6){ref-type="table"}), the Stroop Words delay to be associated with AHI ([Table 7](#T7){ref-type="table"}), and the Stroop Interference delay to be associated with SAS, CSAS, AHI and diabetes ([Table 8](#T8){ref-type="table"}). All three delays were increased in patients with moderate to severe SAS compared to patients with mild to no SAS ([Figure 3](#F3){ref-type="fig"}, Color, *p* = 0.022, Word, *p* = 0.031, Interference, *p* = 0.031). Multivariable regressions revealed that Stroop Color delay increased with age (β = 0.64, CI, 0.09--1.19; *p* = 0.024) and AHI (β = 0.17, CI, 0.02--0.32; *p* = 0.030), that Stroop Words delay increased with AHI (β = 0.31, CI, 0.00--0.62; *p* = 0.047) and that Stroop Interference delay increased in patients with CSAS (β = 24.45, CI, 15.21--50.55; *p* = 0.0024) and in patients with diabetes (β = 32.88, CI, 15.21--50.55; *p* = 0.001).

###### 

Uni- and Multi-variable regression to identify factors associated with the Stroop Colors Test (delay, s).

                                     Univariable   Multivariable (*n* = 60) Backward selection                                   
  ---------------------------------- ------------- --------------------------------------------- ------- ------ ---------------- -------
  Age                                0.79          (0.21--1.36)                                  0.008   0.64   (0.09--1.19)     0.024
  BMI (kg/m^2^)                      0.08          (−0.67--0.83)                                 0.829                           
  Female gender                      4.01          (−3.18--11.20)                                0.269                           
  SAS                                4.24          (−2.35--10.83)                                0.203                           
  OSAS                               1.27          (−5.33--7.87)                                 0.702                           
  CSAS                               1.55          (−6.18--9.28)                                 0.689                           
  Apnea-hypopnea index (AHI)         0.24          (0.08--0.40)                                  0.003   0.17   (0.02--0.32)     0.030
  **Sleep apnea severity**                                                                                                       
  *None*                             REF                                                                                         
  *Mild*                             4.31          (−8.62--17.25)                                0.507                           
  *Moderate*                         3.21          (−6.17--12.60)                                0.496                           
  *Severe*                           8.38          (0.20--16.56)                                 0.045                           
  Blood oxygen saturation (SpO2,%)   −0.47         (−2.05--1.10)                                 0.552                           
  Sleep time with hypoxia^∗^ (%)     −0.03         (−0.26--0.21)                                 0.831                           
  Number of events per night         0.02          (−0.00--0.05)                                 0.063                           
  Diabetes                           6.88          (−2.59--16.34)                                0.151   7.91   (−0.47--16.29)   0.064
  Inflammation                       −1.53         (−8.20--5.14)                                 0.648                           
  Hypercholesterolemia^∗∗^           −5.46         (−18.68--7.75)                                0.411                           
  Hypertriglyceridemia               −0.01         (−8.09--8.07)                                 0.998                           
  Vitamin D deficiency               −5.07         (−11.48--1.35)                                0.119                           
  Anemia                             6.93          (0.22--13.63)                                 0.043   5.98   (−0.07--12.04)   0.053

∗

Hypoxia defined as a reduction of SpO2 by 10%.

∗∗

Excluded from multivariable analysis due to low incidence (\<10).

###### 

Uni- and Multi-variable regression to identify factors associated with the Stroop Words Test (delay, s).

                                     Univariable   Multivariable (*n* = 56) Backward selection                                 
  ---------------------------------- ------------- --------------------------------------------- ------- ------ -------------- -------
  Age                                1.06          (−0.13--2.25)                                 0.081                         
  BMI (kg/m^2^)                      0.70          (−0.70--2.11)                                 0.321                         
  Female Gender                      2.33          (−11.68--16.33)                               0.741                         
  SAS                                8.59          (−4.16--21.35)                                0.182                         
  OSAS                               7.23          (−5.36--19.82)                                0.254                         
  CSAS                               −2.35         (−17.34--12.64)                               0.754                         
  Apnea-hypopnea index (AHI)         0.31          (0.00--0.62)                                  0.047   0.31   (0.00--0.62)   0.047
  **Sleep apnea severity**                                                                                                     
  *None*                             REF                                                                                       
  *Mild*                             15.59         (−8.58--39.76)                                0.201                         
  *Moderate*                                       (−13.97--22.54)                               0.640                         
  *Severe*                           14.59         (−0.90--30.07)                                0.064                         
  Blood oxygen saturation (SpO2,%)   −1.17         (−4.14--1.80)                                 0.433                         
  Sleep time with hypoxia^∗^ (%)     −0.19         (−0.64--0.26)                                 0.393                         
  Number of events per Night         0.04          (−0.01--0.09)                                 0.092                         
  Diabetes                           3.51          (−16.95--23.97)                               0.732                         
  Inflammation                       −2.20         (−15.06--10.66)                               0.733                         
  Hypercholesterolemia^∗∗^           9.81          (−14.91--34.53)                               0.429                         
  Hypertriglyceridemia               0.32          (−15.34--15.99)                               0.967                         
  Vitamin D deficiency               −12.08        (−24.33--0.16)                                0.053                         
  Anemia                             0.05          (−13.33--13.43)                               0.994                         

∗

Hypoxia defined as a reduction of SpO2 by 10%.

∗∗

Excluded from multivariable analysis due to low incidence (\<10).

###### 

Uni- and Multi-variable regression to identify factors associated with the Stroop Interference Test (delay, s).

                                     Univariable   Multivariable (*n* = 50) Backward selection                                    
  ---------------------------------- ------------- --------------------------------------------- ------- ------- ---------------- -------
  Age                                1.29          (−0.05--2.63)                                 0.059   1.13    (−0.05--2.30)    0.061
  BMI (kg/m^2^)                      0.12          (−1.41--1.66)                                 0.872                            
  Female Gender                      5.74          (−9.76--21.24)                                0.460                            
  SAS                                16.93         (3.21--30.66)                                 0.017                            
  OSAS                               1.98          (−12.05--16.01)                               0.778   13.57   (−0.14--27.28)   0.052
  CSAS                               17.18         (2.02--32.33)                                 0.027   24.45   (8.42--40.49)    0.004
  Apnea-hypopnea index (AHI)         0.45          (−0.11--0.78)                                 0.011                            
  **Sleep apnea severity**                                                                                                        
  *None*                             REF                                                                                          
  *Mild*                             --6.02        (−26.26--14.23)                               0.553                            
  *Moderate*                         7.65          (−20.32--35.62)                               0.585                            
  *Severe*                           14.15         (−3.65--31.95)                                0.116                            
  Blood Oxygen Saturation (SpO2,%)   --0.33        (−3.58--2.93)                                 0.840                            
  Sleep Time with hypoxia^∗^ (%)     0.03          (−0.44--0.51)                                 0.890                            
  Number of events per Night         0.04          (−0.02--0.09)                                 0.189                            
  Diabetes                           28.53         (−8.65--48.41)                                0.006   32.88   (15.21--50.55)   0.001
  Inflammation                       --0.52        (−14.80--13.77)                               0.942                            
  Hypercholesterolemia^∗∗^           --12.64       (−42.31--17.02)                               0.395                            
  Hypertriglyceridemia               13.97         (−2.22--30.16)                                0.089                            
  Vitamin D deficiency               --6.85        (−20.71--7.02)                                0.326                            
  Anemia                             8.65          (−5.91--23.21)                                0.238                            

∗

Hypoxia defined as a reduction of SpO2 by 10%.

∗∗

Excluded from multivariable analysis due to low incidence (\<10).
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Discussion {#S4}
==========

The prevalence of SAS in elderly patients admitted to our geriatric unit was 63% (OSAS in 41% and CSAS in 22%), which is considerably higher than that reported in the general population, between 24 and 40% ([@B40]; [@B17]). Our results demonstrated the preeminence of SAS among factors associated with cognitive deficit thus confirming previous observations from the literature ([@B38]; [@B3]; [@B4]; [@B39]). It is worth noting that the prevalence of SAS in our cohort remains higher than recent estimates for the elderly population (25% for men and 42% for women) ([@B17]), which could be due to our great proportion of patients with cognitive deficit ([@B35]; [@B11]). Interestingly, this finding is in agreement with recent observations from German geriatric wards ([@B16]). This study is nevertheless the first to investigate comorbidities associating with SAS while differentiating OSAS and CSAS in this particular population.

The patients in this cohort presented various levels of cognitive deficit, although all were diagnosed with disorders ranging from MCI to AD or vascular dementia. Interestingly, in this diverse cohort, OSAS was identified as an independent predictor of poor MDRS scores but was not associated with MMSE scores. While both tests are used to detect cognitive impairment in the elderly, there are indications that they may not evaluate the same cognitive domains ([@B12]), or that the MDRS may be more specific and sensitive ([@B23]; [@B19]). Furthermore, the ability of the MMSE to efficiently screen for cognitive impairment in the elderly has recently been put into question ([@B14]). It is important to note that the fact that CSAS did not affect MDRS scores in our study could be due to its lower incidence in our cohort and is no proof of lack of effect. Our results also revealed that AHI associates with impaired attention, indicated by the increased delay in the Stroop Colors and Words tests, and that CSAS and perhaps OSAS associate with impaired executive function, indicated by the increased delay in the Stroop Interference test. This is in line with the literature reporting that SAS affects vigilance and the attentional domain ([@B5]) and executive function ([@B5]; [@B38]). In 2012, [@B7] suggested that OSAS may affect vigilance through sleep fragmentation and executive function through hypoxia. In this study, we measured hypoxia and sleep apnea severity (AHI) separately but were not able to verify this hypothesis. It is unclear why, unlike previous literature, AHI rather than oxygen desaturation was associated with cognitive deficit in our cohort, though it could be due to the different manifestations in SAS in the elderly population and in the general population ([@B1]; [@B17]). The relationship between intermittent hypoxia and cognition remain complex, however, and animal studies have suggested that intermittent hypoxia may not directly impair brain structure ([@B21]), but may play a role in the etiology of Alzheimer's Disease ([@B45]; [@B33]; [@B28]). Nevertheless, fragmented sleep and excessive daytime sleepiness have been shown to modify the relationship between AHI and several co-morbidities ([@B37]; [@B42]) and could contribute to cognitive decline in SAS patients ([@B53]). Unfortunately, daytime sleepiness was not evaluated in this study, and could therefore not be included in the multivariable model. We found no association between the number of events per night and cognitive outcomes, though this variable may have underestimated sleep fragmentation, as it did not take snoring into account. The interaction between AHI, sleep fragmentation, daytime sleepiness, and cognitive decline in the elderly remains therefore a question for further search.

We decided to use vascular risk factors known to associate with SAS or AD to adjust the regression models for our cognitive tests. Interestingly, only diabetes independently associated with reduced MMSE and MDRS scores, as well as increased Stroop delay. Taken together, OSAS and diabetes are associated with a reduction of 26 points in the MDRS. Interestingly, severe sleep apnea was shown to be associated with diabetes in the general population ([@B17]). This preeminence of diabetes among risk factors for cognitive deficit has been recently demonstrated ([@B36]) and our results indicate that sleep apnea should be investigated among the other risk factors for the cognitive deficit of the elderly. Indeed, sleep apnea treatment with continuous positive air pressure has shown success in slowing down cognitive decline in the elderly ([@B24]; [@B47]; [@B39]), so that sleep apnea could be considered a modifiable risk factor for cognitive decline in the elderly ([@B2]).

This study is among the first to combine a comprehensive measure of sleep apnea, including the AHI, sleep hypoxia and events per night, with a multivariable regression analysis including known vascular risk factors to determine associations with cognitive deficit in cohort of elderly patients suffering from diffuse cognitive impairment. Moreover, the cohort was controlled for depression and anxiety. The fact that sleep apnea was selected among other well-established risk factors is a powerful demonstration of its association with cognitive deficit in these patients and suggests that sleep apnea ought to be screened for and treated in priority when possible. Further, our distinction of patients suffering primarily from OSAS or CSAS offers novel insight into the effects of these different, yet oftentimes overlapping disorders.

However, this study has several limitations. First, the age of the patients and their cognitive impairment caused a large number of failures of the neurocognitive assessment, especially for the Stroop test. This has weakened our regression analyses and increased the chance of underestimating associations. Second, the fact that patients unable to complete the neurocognitive tests were excluded from the study has created a potential bias, since these patients were likely to exhibit more severe cognitive symptoms. Third, no additional measure of dementia was used to validate MDRS results and assess dementia severity. Fourth, the prevalence of women in our cohort represents the population admitted to our institution, and our results may not be applicable for younger sleep apnea patients, which are predominantly men. Finally, our list of competing risk factors was incomplete, as we were unable to correctly or systematically assess the patients' smoking habits, alcohol consumption, physical inactivity, or daytime sleepiness.

Conclusion {#S5}
==========

This study reveals the high prevalence of sleep apnea in elderly patients with cognitive impairment, and demonstrates the independent association between sleep apnea and cognitive deficit. OSAS was associated with a reduction of the MDRS score, while CSAS was associated with an increased Stroop Interference delay. Our data suggest that elderly patients with cognitive deficit should be screened for sleep apnea and encouraged to follow treatments, if necessary, to prevent cognitive decline.
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